Dr. Sadegh Riazi
Dr. Sadegh Riazi is a technology enthusiast, currently co-founder and CEO of CipherMode Labs. He received his Ph.D. in secure computation from UC San Diego where he was awarded the best Ph.D. thesis award. Sadegh founded Project HEAX at Microsoft Research (a new computing platform for Homomorphic Encryption). Prior to that, he studied Electrical Engineering and designed a new system for Brain-Computer Interfaces. Sadegh is a fellow of the Institute for Global Entrepreneur and has received multiple prestigious awards including Richard Newton Young Fellow Award, Jacobs Graduate Student Award, and Silver Medal in International Student Olympiad.
Dr. Sadegh Riazi
Dr. Sadegh Riazi is a technology enthusiast, currently co-founder and CEO of CipherMode Labs. He received his Ph.D. in secure computation from UC San Diego where he was awarded the best Ph.D. thesis award. Sadegh founded Project HEAX at Microsoft Research (a new computing platform for Homomorphic Encryption). Prior to that, he studied Electrical Engineering and designed a new system for Brain-Computer Interfaces. Sadegh is a fellow of the Institute for Global Entrepreneur and has received multiple prestigious awards including Richard Newton Young Fellow Award, Jacobs Graduate Student Award, and Silver Medal in International Student Olympiad.
Jessica McCreadie
Jess sits in the Health team, and her focus is engaging with, investing in and supporting Europe’s most promising health tech companies.
“The gap between health and life expectancy is widening and to improve quality of life in later years we need a more decentralised, preventative and personalised approach to healthcare.”
Prior to joining Octopus Ventures in June 2021, Jess led the health tech investing team at Legal & General supporting leading health innovations. She invested balance sheet capital into early-stage health tech businesses and supported scale up via board representation in her portfolio.
Earlier in her career Jess invested into and was a banker in a range of alternative asset classes including renewable energy, real estate, and Venture Capital Funds. Jess has a passion for sustainability and delivering social impact alongside economic value.
Outside of work Jess can be found enjoying London’s restaurants, cycling, running, trying out the newest fitness class on offer, or in the park running around with / after her dog.
Wolfgang Hackl
Translational oncology scientist and clinical cancer drug developer with over 20 years of experience directly contributing to pharmaceutical and scientific progress with leading companies worldwide. Proven record of achieving project and organizational objectives by building and leading high- performance teams, promoting cooperation, developing mitigation strategies, and analyzing results to ensure success. Dynamic senior leader with proactive approach to implementing efficient processes and improving staff capabilities. Effective communicator, using interpersonal abilities, active listening, and observational skills to promote genuine, productive discourse. Deeply passionate about cancer research, maintaining a strong vested interest in all assigned projects to drive quality and attain large-scale goals.
Demonstrated success in:
- Leading Femara global registration programs and teaming with colleagues on Aromasin registration.
- Contributing to Proof-of-Concept (POC) for multiple targeted investigational new drugs.
- Delivering expertise across all drug development stages: Discovery, pre-clinical research, POC, phase I to IV development.
- Translating complex concepts into clear, relevant ideas for multilateral understanding and alignment.
- Collaborating to create solutions, improving processes, and building strategies that enable success.
Demonstrated skills in:
Cancer Drug Development · Translational Clinical Oncology · NDA Filing · POC · Biomarker Development · Clinical Studies (Phase I-IV) · Medical Affairs · Wide-Ranging Subject Matter Expertise
- · Team Building · High Performance Leadership · Problem Solving
Sarah Bolt
Anne Morissey
Experienced CEO, innovative strategic thinker, value creator, team builder, connector & fundraiser. Multiple exits, team transitions & global partnerships.
Anne is a passionate leader, driven to ensure positive change to the women's health ecosystem. Anne was named in the 100 Women of MedTech, 2019. Advisor to other CEO's, invited speaker including WSGR Medical Device Conference and the United Nations EWEC.
Kimon Angelides
Kimon Angelides is the founder of six healthcare companies: FemTec Health, Vivante Health, EosHealth which became Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently acquired by Teladoc for $18.5B, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment, provider risk models, and the first remote monitoring of patients, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.
Kimon recently received the 2020 Founder of the Year Award from Rock Health, Goldman Sachs, and PacWest Bank for his contributions and work in digital medicine. Kimon’s newest company, FemTec Health was created in 2020 to bring together all the product and services to create a total healthcare experience for women and to tackle some of the most complex health conditions using state of the art technologies. The company has taken a multidisciplinary approach using digital therapeutics, diagnostics and discovery medicine, devices, and analytics, all taken to enhance and celebrate women’s health and to break some of the taboos associated with women’s sexual wellness. Vivante Health, that Kimon founded in 2016 after Livongo was formed to meet the needs of people who have invisible and stigmatized diseases, starting with digestive health using new advances and innovations in digital health, telemedicine, and biometric devices.
Prior to his healthcare career, Kimon led strategy for Tanox, Inc., a biotech company now part of Genentech, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK building the pre-clinical services for a new medical school, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kimon was on the National Medical Board of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kimon was a Research Career Development Awardee of the National Institutes of Health, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 60 patents. He has a PhD in Bio-organic Chemistry from the University of California and has graduate work in business, laws, and public health.